北欧三国开展品牌特异性流感疫苗效果研究的可行性
研究探讨在丹麦、芬兰和瑞典开展年度品牌特异性流感疫苗效果研究的可行性,起始于2024/25季节。三国拥有可通过个人识别号链接的全民疫苗接种、临床和实验室登记系统,并近实时更新。队列研究采用目标试验模拟框架在三国均可行,而基于登记的检测阴性病例对照设计目前仅在丹麦可行。
要点
- 目标试验模拟框架的队列研究在丹麦、芬兰和瑞典三国均可行。
- 基于登记的检测阴性病例对照设计目前仅在丹麦可行。
- 回归断点分析和阴性对照结局分析可用于处理残余偏倚。
核心结论
- 在丹麦、芬兰和瑞典开展年度品牌特异性流感疫苗效果研究是可行的,其中目标试验模拟框架的队列研究在三国均可行。
研究设计与样本
- 研究探讨在丹麦、芬兰和瑞典开展年度品牌特异性流感疫苗效果研究的可行性,起始于2024/25季节,并讨论合适的研究设计。
主要发现
- 三国维持可通过个人识别号链接的全民疫苗接种、临床和实验室登记系统,并近实时更新。
- 基于目标试验模拟框架的队列研究在三个国家均可行。
- 基于登记的检测阴性病例对照设计目前仅在丹麦可行。
- 回归断点分析和阴性对照结局分析等补充方法可处理残余偏倚。
临床怎么用
- 可利用三国登记系统开展品牌特异性流感疫苗效果评估,为监管和公共卫生决策提供及时真实世界证据。
- 选择研究设计时需考虑各国登记系统可行性差异,队列研究可三国通用,检测阴性设计目前仅丹麦可行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Annual reformulation and approval of seasonal influenza vaccines necessitate yearly evaluation of their effectiveness. Regulatory agencies, including the European Medicines Agency (EMA), rely on timely, real-world evidence to inform product-specific benefit-risk assessments. We explored the feasibility of conducting annual, brand-specific influenza vaccine effectiveness studies in Denmark, Finland and Sweden, starting with the 2024/25 season. These countries maintain population-wide vaccination, clinical and laboratory registers, linkable via personal identification numbers and updated in near real-time. We discuss suitable study designs and document that cohort studies using a target trial emulation (TTE) framework are feasible in all three countries; register-based test-negative case-control design (TND) studies are currently only feasible in Denmark. Supplementary methods, including regression discontinuity and negative control outcome analyses, can address residual bias. This Nordic collaboration has proven capacity for large-scale register-based studies and its infrastructure is able to address EMA's requirements for timely, robust post-authorisation evidence to guide public health and regulatory decisions.
引用
- Faksova K, Thiesson EM, Pihlström N, et al. Feasibility of conducting brand-specific influenza vaccine effectiveness studies in three Nordic countries, Denmark, Finland, Sweden. Euro Surveill. 2026. PMID: 41755720. doi:10.2807/1560-7917.ES.2026.31.8.2500648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。